JP2017524372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524372A5 JP2017524372A5 JP2017515021A JP2017515021A JP2017524372A5 JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5 JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- nos
- isolated
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004335P | 2014-05-29 | 2014-05-29 | |
| US62/004,335 | 2014-05-29 | ||
| PCT/US2015/033129 WO2015184228A1 (en) | 2014-05-29 | 2015-05-29 | Anti-human papillomavirus 16 e7 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Division JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524372A JP2017524372A (ja) | 2017-08-31 |
| JP2017524372A5 true JP2017524372A5 (enExample) | 2018-06-28 |
| JP6742991B2 JP6742991B2 (ja) | 2020-08-19 |
Family
ID=53396593
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515021A Active JP6742991B2 (ja) | 2014-05-29 | 2015-05-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10174098B2 (enExample) |
| EP (3) | EP3689900B1 (enExample) |
| JP (5) | JP6742991B2 (enExample) |
| KR (2) | KR102445667B1 (enExample) |
| CN (2) | CN113150112B (enExample) |
| AU (5) | AU2015266818B2 (enExample) |
| CA (1) | CA2950192A1 (enExample) |
| CY (1) | CY1122790T1 (enExample) |
| DK (1) | DK3149031T3 (enExample) |
| ES (1) | ES2784237T3 (enExample) |
| HR (1) | HRP20200376T1 (enExample) |
| IL (3) | IL290655B2 (enExample) |
| LT (1) | LT3149031T (enExample) |
| MX (2) | MX375379B (enExample) |
| PL (1) | PL3149031T3 (enExample) |
| PT (1) | PT3149031T (enExample) |
| SA (1) | SA516380394B1 (enExample) |
| SI (1) | SI3149031T1 (enExample) |
| SM (1) | SMT202000143T1 (enExample) |
| WO (1) | WO2015184228A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3149031T3 (da) | 2014-05-29 | 2020-03-16 | Us Health | Anti-human papillomavirus 16 e7 t-cellereceptorer |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| RU2019112860A (ru) | 2016-09-27 | 2020-10-30 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов |
| EP3519433A1 (en) * | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| JP7685735B2 (ja) * | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CA3062433A1 (en) * | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| CN110914295B (zh) * | 2017-06-28 | 2024-08-09 | 里珍纳龙药品有限公司 | 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法 |
| AU2018341244A1 (en) | 2017-09-26 | 2020-03-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
| MA50651A (fr) | 2017-09-29 | 2020-08-05 | Us Health | Récepteurs de lymphocytes t reconnaissant p53 mutée |
| EP3692063A1 (en) * | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| CA3077595A1 (en) * | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| EP3707258A1 (en) | 2017-11-06 | 2020-09-16 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN118374524A (zh) | 2018-02-09 | 2024-07-23 | 美国卫生和人力服务部 | 拴系白细胞介素-15和白细胞介素-21 |
| MX2020010235A (es) * | 2018-03-28 | 2020-10-28 | Cero Therapeutics Inc | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. |
| EP3774865A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| EP3775238A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| AU2019247199A1 (en) | 2018-04-05 | 2020-10-15 | Editas Medicine, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| CN112262212B (zh) | 2018-04-24 | 2024-07-12 | 美国卫生和人力服务部 | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |
| WO2019243888A1 (en) * | 2018-06-22 | 2019-12-26 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202101204TA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Processes for generating engineered cells and compositions thereof |
| MX2021002574A (es) | 2018-09-11 | 2021-06-08 | Juno Therapeutics Inc | Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas. |
| JP7713886B2 (ja) | 2018-11-30 | 2025-07-28 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８６バリアント免疫調節タンパク質およびその使用 |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| US12404331B2 (en) | 2019-04-19 | 2025-09-02 | Tcrcure Biopharma Corp. | Anti-PD-1 antibodies and uses thereof |
| AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
| EP3986450A4 (en) * | 2019-06-20 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| WO2020264269A1 (en) | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CN110357952B (zh) * | 2019-07-17 | 2022-03-22 | 深圳市因诺转化医学研究院 | 识别人乳头瘤病毒hpv16-e7抗原的tcr |
| KR20220119439A (ko) | 2019-12-20 | 2022-08-29 | 인스틸 바이오 유케이 리미티드 | 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도 |
| JP7614659B2 (ja) * | 2019-12-30 | 2025-01-16 | ブリスター イムノテック リミテッド | 強化されたｔ細胞受容体ｓｔａｒ及びその用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN113072635B (zh) * | 2020-01-06 | 2023-08-25 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv抗原的t细胞受体及其编码序列 |
| CA3187163A1 (en) * | 2020-05-07 | 2021-11-11 | China Immunotech (Beijing) Biotechnology Co., Ltd | Improved t cell receptor-costimulatory molecule chimera |
| JP7591772B2 (ja) * | 2020-05-25 | 2024-11-29 | ブリスター イムノテック リミテッド | 強化された合成ｔ細胞受容体及び抗原受容体 |
| CN116096740A (zh) * | 2020-06-09 | 2023-05-09 | 得克萨斯州大学系统董事会 | 经改造t细胞受体和使用方法 |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| CN116472050A (zh) | 2020-09-04 | 2023-07-21 | 美国卫生和人力服务部 | 识别p53中r273c或y220c突变的t细胞受体 |
| WO2022060904A1 (en) * | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
| WO2022104035A2 (en) | 2020-11-13 | 2022-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| CN117957245A (zh) | 2021-05-07 | 2024-04-30 | 美国政府(由卫生和人类服务部的部长所代表) | 识别p53中的c135y、r175h或m237i突变的t细胞受体 |
| CN117897411A (zh) * | 2021-06-30 | 2024-04-16 | 华夏英泰（北京）生物技术有限公司 | 一种多靶点合成t细胞受体抗原/抗体受体及其应用 |
| EP4384543A4 (en) * | 2021-09-07 | 2025-06-11 | Corregene Biotechnology Co., Ltd. | ANTIGEN-BINDING PROTEINS AND USES THEREOF |
| JP2024538169A (ja) * | 2021-10-18 | 2024-10-18 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| CA3237646A1 (en) * | 2021-11-10 | 2023-05-19 | Tscan Therapeutics, Inc. | Binding proteins recognizing hpv16 e7 antigen and uses thereof |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| CA3247927A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| CN115286698B (zh) * | 2022-05-10 | 2023-09-01 | 广州医科大学 | 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr |
| WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
| CN116731155B (zh) * | 2022-09-21 | 2024-03-22 | 新景智源生物科技(苏州)有限公司 | 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途 |
| KR20250174626A (ko) | 2023-03-27 | 2025-12-12 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53의 y220c 또는 r175h 돌연변이를 표적화하는 t 세포 수용체 |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| WO2025029835A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for modulating il-2 gene expression |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025096419A1 (en) * | 2023-10-31 | 2025-05-08 | Lyell Immunopharma, Inc. | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025193926A1 (en) | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting e545k or n345k mutation in pik3ca |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| WO2006103429A2 (en) * | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
| AU2007248019B2 (en) * | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| JP6035503B2 (ja) | 2007-05-31 | 2016-11-30 | アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク | ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN110511960B (zh) * | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| DK3149031T3 (da) * | 2014-05-29 | 2020-03-16 | Us Health | Anti-human papillomavirus 16 e7 t-cellereceptorer |
-
2015
- 2015-05-29 DK DK15729004.0T patent/DK3149031T3/da active
- 2015-05-29 EP EP19217074.4A patent/EP3689900B1/en active Active
- 2015-05-29 KR KR1020167033189A patent/KR102445667B1/ko active Active
- 2015-05-29 LT LTEP15729004.0T patent/LT3149031T/lt unknown
- 2015-05-29 SM SM20200143T patent/SMT202000143T1/it unknown
- 2015-05-29 HR HRP20200376TT patent/HRP20200376T1/hr unknown
- 2015-05-29 SI SI201531126T patent/SI3149031T1/sl unknown
- 2015-05-29 EP EP15729004.0A patent/EP3149031B1/en active Active
- 2015-05-29 US US15/313,673 patent/US10174098B2/en active Active
- 2015-05-29 MX MX2016015383A patent/MX375379B/es active IP Right Grant
- 2015-05-29 CA CA2950192A patent/CA2950192A1/en active Pending
- 2015-05-29 CN CN202110399056.9A patent/CN113150112B/zh active Active
- 2015-05-29 CN CN201580031789.XA patent/CN106661098B/zh active Active
- 2015-05-29 EP EP25187143.0A patent/EP4609876A3/en active Pending
- 2015-05-29 JP JP2017515021A patent/JP6742991B2/ja active Active
- 2015-05-29 PL PL15729004T patent/PL3149031T3/pl unknown
- 2015-05-29 WO PCT/US2015/033129 patent/WO2015184228A1/en not_active Ceased
- 2015-05-29 ES ES15729004T patent/ES2784237T3/es active Active
- 2015-05-29 AU AU2015266818A patent/AU2015266818B2/en active Active
- 2015-05-29 IL IL290655A patent/IL290655B2/en unknown
- 2015-05-29 KR KR1020227032043A patent/KR102618267B1/ko active Active
- 2015-05-29 PT PT157290040T patent/PT3149031T/pt unknown
-
2016
- 2016-11-07 IL IL248797A patent/IL248797B/en active IP Right Grant
- 2016-11-24 MX MX2020010035A patent/MX2020010035A/es unknown
- 2016-11-29 SA SA516380394A patent/SA516380394B1/ar unknown
-
2018
- 2018-11-30 US US16/205,631 patent/US10870687B2/en active Active
-
2019
- 2019-12-18 AU AU2019283892A patent/AU2019283892B2/en active Active
-
2020
- 2020-03-16 CY CY20201100238T patent/CY1122790T1/el unknown
- 2020-07-29 JP JP2020127833A patent/JP6997267B2/ja active Active
- 2020-11-23 US US17/101,360 patent/US11434272B2/en active Active
-
2021
- 2021-04-13 AU AU2021202227A patent/AU2021202227B2/en active Active
- 2021-04-21 IL IL282518A patent/IL282518B/en unknown
- 2021-12-16 JP JP2021203953A patent/JP7291196B2/ja active Active
-
2022
- 2022-08-01 US US17/816,496 patent/US12534508B2/en active Active
-
2023
- 2023-02-06 AU AU2023200608A patent/AU2023200608B2/en active Active
- 2023-06-02 JP JP2023091878A patent/JP7535158B2/ja active Active
-
2024
- 2024-08-02 JP JP2024126652A patent/JP7744479B2/ja active Active
- 2024-11-19 AU AU2024266702A patent/AU2024266702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527230A5 (enExample) | ||
| Jee et al. | Immunology of HPV-mediated cervical cancer: current understanding | |
| Baldwin et al. | Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | |
| Davidson et al. | Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) | |
| Klencke et al. | Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101 | |
| Day et al. | In vivo mechanisms of vaccine-induced protection against HPV infection | |
| HRP20200376T1 (hr) | Receptori t-stanica protiv ljudskog papiloma virusa 16e7 | |
| US12551546B2 (en) | Materials and methods relating to immunogenic epitopes from human papilloma virus | |
| Gao et al. | Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector | |
| Shimakage et al. | Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression | |
| Mattil-Fritz et al. | Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles | |
| Vanajothi et al. | HPV-mediated cervical cancer: a systematic review on immunological basis, molecular biology, and immune evasion mechanisms | |
| Dhanushkodi et al. | Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+ CD44+ CD62L− CD8+ T Cells and Memory CCR10+ B220+ CD27+ B Cells into the Infected Vaginal Mucosa | |
| Visalli et al. | Identification of the Epstein Barr virus portal | |
| Afshar Moghaddam et al. | Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview | |
| Mahmoudi et al. | Prostate cancer and human papillomavirus infection: a recent literature review | |
| CN101153059B (zh) | 用于鼻咽癌筛查、诊断和治疗效果预测的elisa试剂盒 | |
| Gao et al. | Identification and characterization of the duck enteritis virus (DEV) US2 gene | |
| Davies et al. | Definition of murine T helper cell determinants in the major capsid protein of human papillomavirus type 16 | |
| Arregui et al. | Oncogenic human papillomaviruses: high-risk human papillomaviruses: towards a better understanding of the mechanisms of viral transformation, latency and immune-escape | |
| Yhee et al. | Characterization of canine oral papillomavirus by histopathological and genetic analysis in Korea | |
| Sauter et al. | Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells | |
| Li et al. | Cervical cancer screening and prevention | |
| Passmore et al. | Host immune responses associated with clearance or persistence of human papillomavirus infections | |
| Li et al. | Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway |